Terns Pharmaceuticals Plans Public Offering to Accelerate Growth
Terns Pharmaceuticals, Inc. (NASDAQ: TERN), a company dedicated to developing advanced oncology treatments, has announced an exciting public offering aimed at raising $400 million. This capital infusion is intended to bolster the company’s clinical programs and innovative research initiatives.
Details of the Proposed Offering
The offering encompasses shares of common stock, along with pre-funded warrants which may be offered to select investors. Additionally, Terns plans to give underwriters the opportunity to purchase up to $60 million in extra shares within a 30-day timeframe. This strategic financial maneuver reflects Terns’ commitment to enhancing its resources and capabilities in a competitive market.
Key Underwriters Involved
To facilitate this offering, Terns has engaged several prominent financial institutions. Jefferies, TD Cowen, and Leerink Partners are designated as the lead book-running managers and will be pivotal in guiding the public offering process. Other collaborators in this venture include Mizuho, Citizens Capital Markets, and Oppenheimer & Co., ensuring that Terns has a robust team backing this significant milestone.
Utilization of Proceeds
The funds generated from this public offering are expected to be utilized for advancing research and clinical trials. Specific focus will be placed on TERN-701, a compound that has shown promise in clinical settings. Additionally, the proceeds will support preparations for a possible commercial launch of TERN-701, solidifying Terns’ position in the industry.
Registration and Compliance Measures
Terns has filed a shelf registration statement with the Securities and Exchange Commission (SEC), which was declared effective. This registration indicates that Terns is compliant with regulatory standards, and the offering will only take place through a well-structured prospectus supplement.
Corporate Overview of Terns Pharmaceuticals
Terns Pharmaceuticals is recognized for its innovative approach in oncology. With a focus on reimagining established biological principles, Terns is committed to delivering impactful medicines. Their lead candidate, TERN-701, has the potential to revolutionize current treatment methodologies for chronic myeloid leukemia (CML), offering improved efficacy and safety.
Contact Information for Inquiries
For more details regarding the offering or company information, interested parties can reach out to:
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
Frequently Asked Questions
What is the purpose of Terns Pharmaceuticals' public offering?
The public offering aims to raise funds to support research, clinical trials, and the development of their product candidates.
Who are the underwriters for this offering?
Jefferies, TD Cowen, and Leerink Partners are the lead underwriters, supported by Mizuho and others.
What is TERN-701?
TERN-701 is Terns' lead clinical candidate, designed to improve treatment options for chronic myeloid leukemia (CML).
How much is Terns aiming to raise in this offering?
Terns is seeking to secure $400 million initially, with an additional $60 million option for underwriters.
Where can I find more information about Terns Pharmaceuticals?
More detailed information can be obtained from their official website or by contacting their investor relations via email.
